A Phase II Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 24 May 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 15 May 2017 Status changed from not yet recruiting to recruiting.
- 27 Mar 2017 Planned initiation date changed from 1 Mar 2017 to 15 Jun 2017.